News and updates

Early detection test GynTect® now available for Roche Diagnostics QPCR system

cobas Z480 Analyzer von Roche Diagnostics oncgnostics GmbH

Jena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) […]

Read more
/by

Oncgnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018

,

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect® […]

Read more
/by

Cervical Cancer Screening: oncgnostics Closes further Investment Round

Das oncgnostics-Teamoncgnostics GmbH

Jena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing […]

Read more
/by

Oncgnostics GmbH retains Biotech Alliances International Inc. to support global partnering and distribution strategy.

Logo Biotech Alliances International

2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering […]

Read more
/by

Cervical Cancer and Uterine (Body) Cancer – What is the Difference?

Cervical CancerBlamb/Shutterstock.com

Although cervical cancer and uterine (body) cancer develop only a few centimetres apart, there are big differences in the cause of the disease. Therefore, the fields of research and treatment […]

Read more
/by

oncgnostics in China: Pitch, Trade Fair, and Meeting with Partner

The oncgnostics managers together with Geneo Dx managers and colleagues.

Dr. Martina Schmitz and Dr. Alfred Hansel, our CSO and CEO, have just come back from a visit in China, with days full of exciting events, dates and a few […]

Read more
/by

Test for Uterine Cancer in Portugal: Biotech Firm oncgnostics Grants Exclusive Licence for Cancer Screening Test

,
Portugal Partnership

Lisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal […]

Read more
/by

Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group

,
Medirex team in Bratislava

Jena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, […]

Read more
/by

GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned

,
Dr. Xia Xiaokai and Dr. Alfred Hansel, chairman of oncgnostics GmbH. In the background: Yang Xiaoming, chairman of CNBG, Wolfgang Tiefensee, Thuringia's Minister for economics, Dr. Michael Brandkamp, chairman of the High-Tech-Gründerfonds sowie Peter Haug, oncgnostics. photo: Christoph Worsch

Jena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) […]

Read more
/by

oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA

Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of […]

Read more
/by